Navigation Links
ICAP Ocean Tomo Announces Auction of Patch Based Drug Delivery and Monitoring Techniques from Entrega Laboratories, LLC

CHICAGO, March 23, 2011 /PRNewswire/ -- Available at ICAP Ocean Tomo's Spring 2011 Live IP Auction, this patent portfolio discloses methods and techniques related to patch-based drug delivery and monitoring.



Administering drugs orally or by injection each has inherent problems. Orally administered drugs (e.g., tablets or pills) pass through the patient's digestive system which breaks down the drug into its constituting components and flushes the rest of the compound out of the body. Consequently, only a small percentage of the administered medicine enters the patient's circulatory system, limiting the drug's effectiveness. This also means that a relatively large intake of medicine is required for effective treatment. Yet, a large dose may adversely affect the patient's digestive system. This can cause many anomalies and harmful side effects.

Drug delivery by injection can be more effective. However, conventional injections may cause pain, require close medical supervision, and add the potential risk of infections. Furthermore, injected medicines cannot be controlled or withdrawn from the body if any adverse effects are observed. In the case of animals, these drug delivery techniques are often risky due to possible aggressive reflex actions during administration of the drug. For these reasons, a safe, controlled and effective alternative method using a transmucosal patch has inherent advantages.

Key Characteristics & Benefits

This patent lot discloses the following:

  • Advanced techniques for delivering drugs through mucosal surface or body tissues of a patient (i.e. human or animal), such as the mouth.
  • This transmucosal drug delivery technique utilizes a medication device (e.g., gum pad) that comprises a semi-permeable package or a tablet matrix containing a prescribed amount of therapeutic medicine.
  • The device also comprises a muco-adhesive portion that assists in attaching the device to body surface (e.g., gums) so that the outer semi-permeable layer is in constant touch with the target mucosal surface for a sufficient time as to allow thorough absorption of the encapsulated medicine by the patient's body.
  • Once the device is attached to the target surface, saliva enters through the semi-permeable outer layer and dissolves the stored medicine. This forms a solution that passes towards the mucosal tissues and is directly absorbed into the body's circulatory system.
  • This facilitates faster and more effective treatment of various diseases.
  • Structural features (i.e., porosity and layer thickness) of the device can be varied to facilitate a controlled release of medicine over a specified time period.
  • This lot also discloses specific drug compositions for treating migraines and a non-invasive technique for measuring/monitoring the blood levels in mammals by attaching a device to their mucosal surface or body tissues.
  • These techniques enable convenient administration of drugs to both human and animal patients, minimizing the risks of dangerous accidents possible with conventional oral or injection based drug delivery techniques.
  • Furthermore, the innovative techniques described may reduce costs associated with veterinarian care as these do not require the procedural costs of a traditional visit.
  • The patents in this lot have been cited by many research institutions as well as industrial giants, such as University of Minnesota, Cephalon and L'Oreal.

Market Potential

This lot should be of interest to pharmaceutical companies, biotechnology firms, healthcare service providers, and entities involved in drug manufacturing and administration.

  • The global market for drug delivery systems is expected to reach $196.4 billion by 2014, while the global market for transmucosal drug delivery systems alone was around $2 billion in 2010. (1)(2)

To learn more about the assets available for sale in this portfolio:

Contact Dean Becker of ICAP Ocean Tomo at

About ICAP Ocean Tomo LLC

ICAP Ocean Tomo is the intellectual property brokerage division of ICAP and the world's premier patent auction firm.

About ICAP

ICAP is the world's premier interdealer broker and provider of post trade services. The Group matches buyers and sellers in the wholesale markets in interest rates, credit, commodities, foreign exchange, emerging markets, equities and equity derivatives through voice and electronic networks. ICAP plc was added to the FTSE 100 Index on 30 June 2006. For more information go to



Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. The Ocean Becomes a Pipeline To A Cure for Cystic Fibrosis
2. Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing
3. Oceanside Pharmaceuticals Announces Launch of Librax(R) AG
4. ICAP Ocean Tomo Offers IP Portfolio of Near-Infrared Spectroscopy Technology
5. ICAP Ocean Tomo Offers for Sale Advanced Drug Formulation Technology From CyDex Pharmaceuticals Inc.
6. ICAP Ocean Tomo Offers for Sale IP Portfolio of Active Implants for Electromagnetic Bone and Tissue Regeneration in Orthopedics, Trauma, and Wound Care
7. Skin Lesion Identification System to Auction on November 11th at ICAP Ocean Tomos Fall 2010 Live IP Auction
8. ICAP Ocean Tomo to Auction 7 Exclusive Licenses from Lawrence Livermore National Laboratory at Fall Auction November 11th in Napa, California
9. Cutting Edge Nanotech Patents for Displays, Lighting, X-ray, Medical Imaging, and Diagnostics Available for Sale by ICAP Ocean Tomo
10. ICAP Ocean Tomo Announces Patents for a New and Safer Method of Treatment of Osteoporosis and Tumor Metastasis Using a Novel Zoledronic Acid Combination
11. ICAP Ocean Tomo Announces Advanced Techniques for Measuring Blood Pressure From Coherence L.L.C.
Post Your Comments:
(Date:12/1/2015)... During the recent 2015 Transcatheter Cardiovascular ... CA , Medinol Ltd. continued to introduce ... a satellite symposium, "The BioNIR eDES: The Role ... a renowned physician panel discussed the key attributes ... Stent System and the Medinol eDES Coronary Stent ...
(Date:12/1/2015)... YORK , Dec. 1, 2015 Relmada Therapeutics, ... the treatment of chronic pain, announced today that the company ... will be held December 1-3 at the Luxe Sunset Boulevard ... Sergio Traversa , CEO of Relmada Therapeutics, will present on ... Eastern Time). . Please register at least ...
(Date:12/1/2015)... Dec. 1, 2015  InCarda Therapeutics, Inc. (InCarda), a ... of therapies for cardiovascular conditions via the inhalation route, ... in Australia . InCarda is planning ... Australia in the first half of ... medical centers in Adelaide and ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... Baptist Medical Center ... and is the only hospital in the region providing what is known as ... transcatheter pacing patients were revealed recently at a medical conference and published in ...
(Date:12/1/2015)... MD (PRWEB) , ... December 01, 2015 , ... ... salmon identification tests to continue the expansion of the company’s growing product line ... – for Chinook (Oncorhynchus tshawytscha) and Sockeye (Oncorhynchus nerka) – allow InstantLabs to ...
(Date:12/1/2015)... New York, NY (PRWEB) , ... December 01, ... ... cause of non-traumatic limb amputations in the United States. Podiatrists are well aware ... (failure to adopt therapeutic behaviors) are often catastrophic contributors to diseases of the ...
(Date:12/1/2015)... CA (PRWEB) , ... December 01, 2015 , ... ... Health Center of Excellence (BHCOE) today announced that the organization has awarded Education ... San Francisco, with a Distinguished Award. The award celebrates exceptional special needs providers ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... for Effective Post-Affiliation Integration ,” addresses a main “pain point” for merging or ... anticipated results, once a deal is signed. This quick-read guidance suggests that ...
Breaking Medicine News(10 mins):